![]() |
市場調査レポート
商品コード
1348005
アポトーシスアッセイの世界市場-2023年~2030年Global Apoptosis Assays Market - 2023-2030 |
||||||
カスタマイズ可能
適宜更新あり
|
アポトーシスアッセイの世界市場-2023年~2030年 |
出版日: 2023年09月11日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
|
アポトーシスアッセイは、カスパーゼ活性化、ホスファチジルセリン(PS)の細胞表面露出、DNA断片化など、プログラムされた細胞死に関連する細胞イベントを検出し、定量します。細胞アポトーシスは、アネキシンV、カスパーゼ、TUNEL DNA断片化アッセイを用いてプログラムされた細胞死を検出・評価します。
細胞ベースのアッセイは、アポトーシスのタイムラインにわたる特定の細胞死プロセスを検出します。アポトーシスアッセイキットと試薬は、細胞のライフサイクルの自然な一部であるプログラム細胞死の調査に利用できます。
アポトーシスアッセイキットは、アポトーシス細胞、壊死細胞、健常細胞を同時にモニターするように設計されています。革新的なアポトーシスキットは高度な技術と技術的手順を提供し、調査時間を短縮します。このように、これらの要因がキットの需要を増加させ、市場成長を牽引しています。
例えば、2022年12月9日、TransGen社は、フローサイトメトリーまたは蛍光顕微鏡を用いた早期アポトーシス検出のための異なるプローブと色素を用いた4種類のアネキシンV検査キットを発表しました。これらのキットは操作が簡単で、高感度かつ特異的で、細胞の初期アポトーシスを検出するのに適しています。
さらに、2022年9月20日、ナノライブ社は、細胞の健全性、死、アポトーシス、ネクローシスをラベルフリーでプロファイリングするプッシュボタン式の自動化ソリューションであるLIVE細胞死アッセイを販売しました。機械学習(ML)アルゴリズムに基づき、細胞オブジェクトを完全にラベルフリーで生死を分類し、アポトーシス細胞と壊死細胞を区別します。
加えて、新規治療薬の増加や先進治療開発のためのがん研究数の増加が市場成長の促進要因として作用しています。
抗がん剤の開発コストの高さは、アッセイのコストに影響を与える可能性があります。新薬1種類あたりの平均研究開発費は100万米ドル未満から200万米ドル以上と推定されています。例えば、ジヌツキシマブは小児リスクの神経芽腫の固形化後療法に使用される薬剤で、開発コストは2億7,600万米ドルです。このように、薬剤の開発コストの高さは市場の成長に影響を与える可能性があります。
Apoptosis assay detects and quantifies the cellular events associated with programmed cell death, including caspase activation, cell surface exposure of phosphatidylserine (PS), and DNA fragmentation. Cellular apoptosis assays to detect programmed cell death using Annexin V, Caspase, and TUNEL DNA fragmentation assays.
Cell-based assays detect specific cell death processes across the apoptotic timeline. Apoptosis assay kits and reagents are available for investigations in programmed cell death, a natural part of the cell's life cycle.
Apoptosis Assay Kit is designed to monitor apoptotic, necrotic, and healthy cells simultaneously. Innovative apoptosis kits offer advanced technologies and technological procedures, which reduces the time in research studies. Thus, these factors increase the demand for the kits, which drives the market growth.
For instance, on December 9, 2022, TransGen introduced 4 Annexin V testing kits with different probes and dyes for early apoptosis detection using flow cytometry or fluorescence microscopy. These kits are easy to operate, highly sensitive and specific, and are suitable for detecting early apoptosis of the cells.
Additionally, on September 20, 2022, Nanolive marketed the LIVE Cell Death Assay, a push button, automated solution for profiling cell health, death, apoptosis, and necrosis, label-free. Based on a machine learning (ML) algorithm, it classifies cellular objects completely label-free as living or dead, distinguishing apoptotic and necrotic cells.
Additionally, the increase in novel therapeutics and the increase in the number of cancer research for developing advanced treatments act as driving factors of the market growth.
Higher costs of developing a cancer drug can impact the cost of the assays. It is estimated that the average R&D cost per new drug ranges from less than $1 Million to more than $2 Million per drug. For instance, Dinutuximab, a drug used for post-consolidation therapy for childhood-risk neuroblastoma, costs $276 million to develop. Thus, the high cost of developing a drug can affect the market growth.
The global apoptosis market is segmented based on product, detection technology, application, end-user, and region.
The flow cytometry segment holds a significant position in the apoptosis assay market share due to the efficiency of the technique over the other methods. It is one of the most popular and versatile applications for studying apoptosis. It offers the ability to study large numbers of cells individually rather than in a mixed population, examining simultaneously the expression of many proteins like cell-specific markers and indicators of apoptosis.
It has wide applications in the pharmaceutical industry because it provides a way to understand the drug's mechanism of action in the drug discovery process. To stratify a better target for patients, it is necessary to understand the mechanism of drug action, which flow cytometry does.
On June 3, 2022, BD launched an advanced flow cytometry system that sorts cells based on their inner workings. The new BD FACSDiscover S8 Cell Sorter features the breakthrough BD cell view image technology.
Additionally, it has a variety of applications in research and development. Flow Cytometry detects changes in the plasma and mitochondrial membranes, caspase activity, nuclear condensation, and fragmentation as possible indicators of apoptosis. Flow cytometry allows the study of all aspects of apoptosis, from induction via surface receptors, to late stages where DNA fragmentation occurs. Thus, the above factors allow the usage of a flow cytometer in apoptosis studies. Thus, flow cytometry holds a significant market share.
An increase in the development of anticancer drugs in the region is expected to hold the region in the dominant market share. Apoptosis assays elucidate the cell death-related events during tumor cell killing by anti-cancer drugs. Apoptosis assays are available for single and multi-time point analysis as well as real-time live-cell imaging. Many anticancer drugs are designed to kill cells by inducing apoptosis.
The increase in the number of cancer cases is influencing the development and launches of new drugs, thus increasing the region's market share. For instance, according to the American Cancer Society, it is estimated that 1.9 million new cancer cases have been diagnosed and 609,360 cancer deaths in the United States in 2022. Thus, increasing the development of drugs for the treatment of cancer.
An increase in the development and approvals of anticancer drugs increases apoptosis studies to evaluate the mechanism of the drug. For instance, on September 2, 2022, the FDA approved durvalumab in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer. Thus, the number of anticancer drug approvals is expected to hold the region in the dominant position in the apoptosis assays market
COVID-19 has impacted the growth of the apoptosis assays market. The shift of focus to research and developing novel products for treating COVID-19 has created a negative impact on the apoptosis assays market growth. The delay in approvals of the kits has also affected the market growth. The delay in drug discovery has also impacted the apoptosis assays market.
The global apoptosis assays market is fragmented, with the presence of many local and international players. Thermo Fisher Scientific Inc., Elabscience Biotechnology Inc., Bio-Rad Laboratories, Merck KGaA, Molecular Devices, LLC., Becton, Dickinson, and Company, Bio-Techne Corporation., Promega Corporation., BPS Bioscience Inc., and Agilent Technologies, Inc. are the leading companies with a significant market share.
The global apoptosis assays market report would provide approximately 59 tables, 70 figures, and 186 Pages.
LIST NOT EXHAUSTIVE